{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-016245","form_type":"8-K","ticker":"SANA","cik":"0001770121","company_name":"Sana Biotechnology, Inc.","filed_at":"2023-01-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.475970+00:00","generated_at":"2026-06-20T08:23:27.818283+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"FDA clears Sana's IND for SC291 allogeneic CAR T therapy in B-cell malignancies","bullets":["SC291 is a CD19-targeted allogeneic CAR T cell therapy using Sana's hypoimmune platform.","FDA clearance allows first-in-human study in patients with B-cell lymphomas and leukemias.","Company expects initial clinical data from SC291 study later in 2023.","Plans to submit a second IND this year for SC262, a CD22-targeted allogeneic CAR T therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-016245","json":"https://secwatch.observer/filing/0001193125-23-016245.json","markdown":"https://secwatch.observer/filing/0001193125-23-016245.md","text":"https://secwatch.observer/filing/0001193125-23-016245.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770121/000119312523016245/0001193125-23-016245-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770121/000119312523016245/d642303d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T08:23:27.818283+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}